Nuvalent Q3 net loss $122.4M; completes NDA for zidesamtinib; cash $943M into 2028

Nuvalent, Inc.

2025-Q3 EPS reported -$4.27

Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC.
On track to report topline pivotal data for neladalkib in ALK-positive NSCLC by year-end 2025.
Cash, cash equivalents and marketable securities of $943.1M as of Sept 30, 2025; expected runway into 2028.
Q3 2025 net loss of $122.4M, R&D expenses $83.8M, G&A expenses $28.9M.
Presented preliminary data for neladalkib in ALK-positive solid tumors at ESMO and preclinical data for NVL-330 in HER2-altered NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.